Zydus Cadila’s arm gets USFDA’s nod for Dextroamphetamine Saccharate

19 Jul 2019 Evaluate

Zydus Cadila’s US arm -- Nesher Pharmaceuticals has received the final approval from the US Food and Drug Administration (USFDA) to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, Extended Release Capsules, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.

The drug is indicated for the treatment of Attention-Deficit Hyperactivity Disorder which is a brain disorder characterized by an ongoing pattern of inattention and, or hyperactivity-impulsivity that interferes with functioning or development. It will be manufactured at Nesher Pharmaceuticals’ manufacturing facility located at St. Louis, MO, USA.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×